文献速递免疫规划

BNT162b2 mRNA COVID-19疫苗首剂接种者中的一过性感觉症状:病例对照研究

Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study.
PubMed 文献 · Vaccine · 2021-10-29

该病例对照研究从7,812,845名BNT162b2首剂接种者中评估免疫接种后非特异性感觉症状(NSSS),其中10,929人报告免疫接种后不良事件(AEFI)。NSSS总体频率为3.4%(377例),即每10万剂4.8例;手臂(61%)和面部/颈部(36.2%)最常受累。对照组反应原性相关症状发生率显著更高,提示NSSS不依赖反应原性;多变量分析中医护人员报告感觉症状的频率较低(aOR 0.54;95% CI 0.40-0.72;p < 0.001)。

要点

  • BNT162b2首剂接种者中NSSS总体频率为3.4%(377例),即每10万剂4.8例。
  • NSSS最常累及手臂(61%)和面部/颈部(36.2%)。
  • 多变量分析中医护人员报告感觉症状的频率较低(aOR 0.54;95% CI 0.40-0.72;p < 0.001)。

核心结论

  • NSSS在BNT162b2首剂接种者中总体频率为3.4%(377例)或每10万剂4.8例,其良性性质可能有助于消除对该疫苗的犹豫。

研究设计与样本

  • 病例对照研究,从7,812,845名BNT162b2首剂接种者中评估NSSS,其中10,929人报告AEFI。

主要发现

  • NSSS总体频率为3.4%(377例)或每10万剂4.8例。
  • 解剖学上手臂(61%)和面部/颈部区域(36.2%)为最常受累部位。
  • 对照组反应原性相关症状发生率显著更高,提示NSSS不依赖反应原性。
  • 多变量分析中医护人员报告感觉症状的频率较低(aOR 0.54;95% CI 0.40-0.72;p < 0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

mRNA-based COVID-19 vaccines are effective; however, persistent vaccine hesitancy is partly due to a misperception of their potential adverse events. Non-specific sensory symptoms (NSSS) following immunization are thought to be mediated by stress-related responses. In this case-control study, we evaluated NSSS from a cohort of 7,812,845 BNT162b2 first-dose recipients, of whom 10,929 reported an adverse event following immunization (AEFI). We found an overall frequency of 3.4% (377 cases) or 4.8 cases per 100,000 doses administered. Anatomically, the arms (61%) and face/neck region (36.2%) were the most commonly affected sites. The control group had significantly higher rates of reactogenicity-associated symptoms, suggesting that NSSS are reactogenicity-independent; in multivariable analysis, healthcare workers reported sensory symptoms less frequently (aOR 0.54; 95% CI 0.40-0.72;p < 0.001). This is the first study describing the topography and associated factors for developing NSSS among BNT162b2 recipients. The benign nature of these symptoms may help dissipate hesitation towards this vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. García-Grimshaw M, Ceballos-Liceaga SE, Michel-Chávez A, et al. Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study. Vaccine. 2021. PMID: 34742595. doi:10.1016/j.vaccine.2021.10.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。